Thermo Fisher Scientific Inc. TMO focuses on expanding through the acquisition of technologies and businesses that augment its existing products and services. The company continues to enhance its ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways produced impressive improvements in hair regrowth during and after therapy.

Key takeaways: Patients with severe to very severe alopecia areata saw hair regrowth with bempikibart treatment within 24 weeks. Hair regrowth seemed to persist after treatment cessation to week 36.

References: 1 Passeron T, et al. Baricitinib provides significant hair regrowth in adolescents with severe alopecia areata: 36-week efficacy and safety results from a Phase 3 randomized, controlled ...

WALTHAM, Mass.-- (BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry ...

HCW Biologics receives FDA IND clearance to begin a Phase 1 trial of HCW9302 for alopecia areata treatment.

While not life-threatening, alopecia areata has no cure. Existing off-label treatments may provide some relief of symptoms, but there are often dangerous side effects.

Log-binomial regression models revealed a 3.3-fold increased prevalence of alopecia areata among South Asian children compared with non-Hispanic White children.

Alopecia areata and asthma are strongly linked, particularly through the inflammatory protein IL-33, suggesting a shared biological pathway and potential for targeted treatments like dupilumab.

This model parallels a natural exposure and potential intranasal sensitization-to-pathology paradigm and supports the plausibility that nasopharyngeal subclinical BP colonization is a cause of ...

Alopecia Areata is an autoimmune disorder where the body’s immune system attacks normal cells instead of intruders, leading to hair loss. If not detected early, it can progress to complete scalp ...